drugset

drugset / Trial / NCT03921411

A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)

NCT03921411 ↗

Phase 2 Completed 20 enrolled Galderma R&D

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to evaluate the pharmacokinetics and safety of nemolizumab in adolescent participants with AD.

Timeline

Start: 2019-04-09
Primary completion: 2020-08-19
Completion: 2020-08-19

Publications

Sidbury R, Alpizar S, Laquer V, Dhawan S, Abramovits W, Loprete L, Krishnaswamy JK, Ahmad F, Jabbar-Lopez Z, Piketty C. Pharmacokinetics, Safety, Efficacy, and Biomarker Profiles During Nemolizumab Treatment of Atopic Dermatitis in Adolescents. Dermatol Ther (Heidelb). 2022 Mar;12(3):631-642. doi: 10.1007/s13555-021-00678-7. Epub 2022 Jan 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nemolizumab	Monoclonal antibody	30 mg	Subcutaneous

Indications